Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats

European Journal of Pharmacology

Volumn 659, Issue 2-3, 2011, Pages 213-223

  Ghatak, Somsuvra B ^a   Dhamecha, Prakash S ^b   Bhadada, Shraddha V ^a   Panchal, Shital J ^a  

^a NIRMA UNIVERSITY   (India)

^b Torrent Pharmaceuticals Ltd   (India)

Author keywords

Hyperlipidemia; Metformin; Oxidative stress; Thrombosis

Indexed keywords

ANTIOXIDANT; ATORVASTATIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NITRITE; TRIACYLGLYCEROL; TRITON X 100; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING TIME; BODY WEIGHT; CARDIOVASCULAR RISK; CAROTID ARTERY THROMBOSIS; CELL DAMAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; FOOD INTAKE; HYPERLIPIDEMIA; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; RISK REDUCTION; THROMBOSIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; AORTA; ATHEROSCLEROSIS; BLOOD COAGULATION; BODY WEIGHT; CAROTID ARTERIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EATING; FEMALE; FIBRINOGEN; HYPERLIPIDEMIAS; LIPID PEROXIDATION; MALE; METFORMIN; NITRITES; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; THROMBOSIS;

EID: 79955942629     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.029     Document Type: Article

References (49)

1. Aebi, H.E., 1983. Catalase, in methods of enzymatic analysis, In: Bergmeyer, H.U., Bergmeyer, J., Grabl, M. (Eds.), third ed. Verlag Chemie, New York, pp. 273-286. 3.
2. Beisswenger, P., Ruggiero-Lopez, D., 2003. Metformin inhibition of glycation processes. Diabetes Metab. 29, 6S95-6S103.
3. Davis, B.J., Xie, Z., Viollet, B., Zou, M.H., 2006. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55, 496-505. (Pubitemid 43343281)
4. Defronzo, R.A., Goodman, A.M., 1995. Efficacy of metformin in patient with non-insulin dependent diabetes mellitus. N. Engl. J. Med. 333, 541-549.
5. Detaille, D., Guigas, B., Chauvin, C., 2005. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 54, 2179-2187. (Pubitemid 40911282)
6. Diaz, M.N., Frei, B., Vita, J.A., Keaney, J.F., 1997. Antioxidants and atherosclerotic heart disease. N. Engl. J. Med. 337, 408-416.
7. Eriksson, A., Attval, S., Bonnier, M., Eriksson, J.W., Rosander, B., Kalrsson, F.A., 2007. Short-term effects of metformin in type 2 diabetes. Diabetes Obes. Metab. 9, 483-489.
8. Eurich, D.T., Majumdar, S.R., McAlister, F.A., Tsuyuki, R.T., Johnson, J.A., 2005. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28, 2345-2351. (Pubitemid 41384275)
9. Gallo, A., Ceolotto, G., Pinton, P., Iori, E., Murphy, E., Rutter, G.A., 2005. Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes 54, 1123-1131. (Pubitemid 40446327)
10. Glass, C.K., Witztum, J.L., 2001. Atherosclerosis: the road ahead. Cell 104, 503-516. (Pubitemid 32201946)
11. Griess, P., 1879. Bemerkungen zu der abhandlung der H.H. Weselsky und Benedikt "Ueber einige azoverbindungen". Chem. Ber. 12, 426-428.
12. Griffin, J.H., Kojima, K., Banka, C.L., 1999. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. 103, 219-227.
13. Griffin, J.H., Fernandez, J.A., Deguchi, H., 2001. Plasma lipoproteins, hemostasis and thrombosis. Thromb. Haemost. 86, 386-394.
14. Gryglewski, R.J., Palmer, R.M.J., Moncada, S., 1986. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320, 454-456. (Pubitemid 16097810)
15. Isoda, K., Young, J.L., Zirlik, A., MacFarlane, L.A., Tsuboi, N., Gerdes, N., 2006. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 26, 611-617.
16. Izkhakov, E., Meltzer, E., Rubinstein, A., 2003. Pathogenesis and management of diabetic dyslipidemia. Treat. Endocrinol. 2, 231-245.
17. Johnson, J.A., Majumdar, S.R., Simpson, S.H., Toth, E.L., 2002. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25, 2244-2248. (Pubitemid 41071035)
18. Juan, F., Viles, G., Valentin, F., Juan, J.B., 2004. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur. Heart J. 25, 1197-1207.
19. Kumar, V.B., Bernardo, A.E., Vyas, K., Franko, M., Farr, S., Lakshmanan, L., Buddhiraju, C., Morley, J.E., 2001. Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice. Life Sci. 69, 2789-2799. (Pubitemid 33000319)
20. Kumar, V., Cotrans, R.S., Robbins, S.L., 2005. Robbins Basic Pathophysiology, seventh ed. Elsevier publication, Philadelphia, pp. 328-338.
21. Kurz, K.D., Main, B.W., Sandusky, G.E., 1990. Rat model of arterial thrombosis induced by ferric chloride. Thromb. Res. 60, 269-280.
22. Landin, K., Tengborn, L., Smith, U., 1994. Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb. Haemost. 71, 783-787.
23. Maccallum, P.K., Cooper, J.A., Martin, J., 2000. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma. Thromb. Haemost. 83, 421-426.
24. Mather, K.J., Verma, S., Anderson, T.J., 2001. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 37, 1344-1350.
25. McAfee, A.T., Koro, C., landon, J., Ziyadeh, N., Walker, A.M., 2007. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol. Drug Saf. 16, 711-725.
26. Mehta, K., Balaraman, R., Amin, A.H., Bafna, P.A., Gulati, O.D., 2003. Effect of fruits of Moringa oleifera on the lipid profile of normal and hypercholesterolaemic rabbits. J. Ethnopharmacol. 86, 191-195. (Pubitemid 36542876)
27. Mirjana, B., 2007. Pathogenetic aspects of atherosclerosis. Acta Med. Medianae 46, 25-29.
28. Misra, H.P., Fridovich, I., 1972. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 247, 3170-3179.
29. Moron, M.J., Diperre, J.W., Mannerv, K.B., 1979. Levels of glutathione, glutathione reductase and glutathione-S-transferase activities in rat lungs and liver. Biochem. Biophys. Acta 582, 67-71.
30. Moyer, M.P., Tracy, R.P., Tracy, P.B., 1998. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler. Thromb. Vasc. Biol. 18, 458-465.
31. Murray, C.J., Lopez, A.D., 1997. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 349, 1269-1276. (Pubitemid 27192468)
32. Ohkawa, H., Ohishi, N., Yagik, S., 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351-358.
33. Parhofer, K.G., Laubach, E., Geiss, H.C., Otto, C., 2002. Effect of glucose control on lipid levels in patients with type 2 diabetes. Dtsch. Med. Wochenschr. 127, 958-962.
34. Pradhan, R.K., Chakravarthy, V.S., Prabhakar, A., 2007. Effect of chaotic vasomotion in skeletal muscle on tissue oxygenation. Microvasc. Res. 74, 51-64.
35. Ross, R., 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809. (Pubitemid 23132154)
36. Rubanyi, G.M., Vanhoutte, P.M., 1986. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am. J. Physiol. 250, H822-H827.
37. Russell, J.C., Koeslag, D.G., Dolphin, P.J., Amy, R.M., 1990. Prevention of myocardial lesions in JCR:LA-corpulent rat by nifedepine. Arteriosclerosis 10, 658-664. (Pubitemid 20220591)
38. Sartoretto, J.L., Melo, G.A., Carvalho, M.H., Nigro, D., Passaglia, R.T., Scavone, C., Cuman, R.K., Fortes, Z.B., 2005. Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin induced diabetic rats increasing NOS activity, but not NOS expression. Life Science 77, 2676-2689. (Pubitemid 41262241)
39. Schumacher, W.A., Bostwick, J.S., Ogletree, A.B., Hua, J., Rehfuss, R.P., 2007. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats. J. Pharmacol. Exp. Ther. 322, 369-377.
40. Sharma, A., Mathur, R., Dixit, V.P., 1995. Prevention of hypercholesterolemia and atherosclerosis in rabbits after supplementation of Myristica fragrans seed extract. Indian J. Physiol. Pharmacol. 39, 407-410.
41. Sheela, C.G., Augusti, K.T., 1995. Antiperoxide effects of S-allyl cysteine sulfoxide isolated from Allium sativum Linn. and gugulipid in cholesterol fed rats. Indian J. Exp. Biol. 33, 337-341.
42. Standeven, K.F., Ariens, R.A., Whitaker, P., Ashcroft, A.E., Weisel, J.W., Grant, P.J., 2002. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51, 189-197. (Pubitemid 34517997)
43. Starsky, A., Ellis, B.C., 1961. A quick and accurate method for determination of fibrinogen in plasma. J. Lab. Clin. Med. 59, 477-488.
44. Turner, R.C., Holman, R.R., Stratton, I.M., 1998. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865.
45. Visavadiya, N.P., Narasimhacharya, A.V., 2005. Hypolipidemic and antioxidant activities of Asparagus racemosus in hypercholesteremic rats. Indian J. Pharmacol. 37, 376-380.
46. Wiernsperger, N.F., Bouskela, E., 2003. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab. 29, 6S77-6S87.
47. Wu, T., Rifai, N., Roberts, L.J., Willett, W.C., Rimm, E.B., 2004. Stability of measurements of biomarkers of oxidative stress in blood over 36 hours. Cancer Epidemiol. Biomarkers Prev. 13, 1399-1402.
48. Wu, T., Willett, W.C., Rifai, N., Rimm, E.B., 2007. Plasma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studies. Am. J. Epidemiol. 166, 552-560.
49. Zou, M.H., Kirkpatrick, S.S., Davis, B.J., Nelson, J.S., Wiles, W.G., Schlattner, U., Neumann, D., Brownlee, M., Freeman, M.B., Goldman, M.H., 2004. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo: role of mitochondrial reactive nitrogen species. J. Biol. Chem. 279, 43940-43951.